1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90. PMID:
21296855.
3. Hoseini S, Moaddabshoar L, Hemati S, Mohammadianpanah M. An overview of clinical and pathological characteristics and survival rate of colorectal cancer in Iran [abstract]. Ann Colorectal Res 2014;2:e17264.
4. Omidvari S, Hamedi SH, Mohammadianpanah M, Razzaghi S, Mosalaei A, Ahmadloo N, et al. Comparison of abdominoperineal resection and low anterior resection in lower and middle rectal cancer. J Egypt Natl Canc Inst 2013;25:151–160. PMID:
23932752.
5. Kye BH, Cho HM. Overview of radiation therapy for treating rectal cancer. Ann Coloproctol 2014;30:165–174. PMID:
25210685.
6. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638–646. PMID:
11547717.
7. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575–582. PMID:
21596621.
8. Sun Myint A, Mukhopadhyay T, Ramani VS, Perkins K, Snee AJ, Jelley F, et al. Can increasing the dose of radiation by HDR brachytherapy boost following preoperative chemoradiotherapy for advanced rectal cancer improve surgical outcomes? Colorectal Dis 2010;12(Suppl 2): 30–36. PMID:
20618365.
9. Webster MJ, Devic S, Vuong T, Yup Han D, Park JC, Scanderbeg D, et al. Dynamic modulated brachytherapy (DMBT) for rectal cancer. Med Phys 2013;40:011718PMID:
23298088.
10. Webster MJ, Devic S, Vuong T, Han DY, Scanderbeg D, Choi D, et al. HDR brachytherapy of rectal cancer using a novel grooved-shielding applicator design. Med Phys 2013;40:091704PMID:
24007137.
11. Lavertu S, Schild SE, Gunderson LL, Haddock MG, Martenson JA. Endocavitary radiation therapy for rectal adenocarcinoma: 10-year results. Am J Clin Oncol 2003;26:508–512. PMID:
14528081.
12. Aumock A, Birnbaum EH, Fleshman JW, Fry RD, Gambacorta MA, Kodner IJ, et al. Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumors. Int J Radiat Oncol Biol Phys 2001;51:363–370. PMID:
11567810.
13. Coatmeur O, Truc G, Barillot I, Horiot JC, Maingon P. Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy. Radiother Oncol 2004;70:177–182. PMID:
15028405.
14. Gerard JP, Frin AC, Doyen J, Zhou FX, Gal J, Romestaing P, et al. Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud - nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. Acta Oncol 2015;54:545–551. PMID:
25389568.
15. Birnbaum EH, Ogunbiyi OA, Gagliardi G, Fry RD, Myerson RJ, Kodner IJ, et al. Selection criteria for treatment of rectal cancer with combined external and endocavitary radiation. Dis Colon Rectum 1999;42:727–733. PMID:
10378596.
16. American Joint Committee on Cancer Colon and rectum. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York, NY: Springer-Verlag; 2010. p. 143–164.
17. Han JW, Lee MJ, Park HK, Shin JH, An MS, Ha TK, et al. Association between a close distal resection margin and recurrence after a sphincter-saving resection for t3 mid- or low-rectal cancer without radiotherapy. Ann Coloproctol 2013;29:231–237. PMID:
24466537.
18. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006;65:1129–1142. PMID:
16750329.
19. Appelt AL, Vogelius IR, Ploen J, Rafaelsen SR, Lindebjerg J, Havelund BM, et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 2014;90:110–118. PMID:
25015203.
20. Christoforidis D, McNally MP, Jarosek SL, Madoff RD, Finne CO. Endocavitary contact radiation therapy for ultrasonographically staged T1 N0 and T2 N0 rectal cancer. Br J Surg 2009;96:430–436. PMID:
19283737.
21. Gerard JP, Chapet O, Ortholan C, Benezery K, Barbet N, Romestaing P. French experience with contact X-ray endocavitary radiation for early rectal cancer. Clin Oncol (R Coll Radiol) 2007;19:661–673. PMID:
17822887.
22. Gerard JP, Ayzac L, Coquard R, Romestaing P, Ardiet JM, Rocher FP, et al. Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon's technique. Int J Radiat Oncol Biol Phys 1996;34:775–783. PMID:
8598353.
23. Vuong T, Devic S, Podgorsak E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol) 2007;19:701–705. PMID:
17714925.
24. Smith JA, Wild AT, Singhi A, Raman SP, Qiu H, Kumar R, et al. Clinicopathologic comparison of high-dose-rate endorectal brachytherapy versus conventional chemoradiotherapy in the neoadjuvant setting for resectable stages II and III low rectal cancer. Int J Surg Oncol 2012;2012:406568PMID:
22830003.
25. Kuvshinoff B, Maghfoor I, Miedema B, Bryer M, Westgate S, Wilkes J, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? Ann Surg Oncol 2001;8:163–169. PMID:
11258782.
26. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124–5130. PMID:
19770376.
27. El-Sayed ME, El-Taher ZH. Prospective phase II study of brachytherapy boost as a component of neo-adjuvant chemotherapy and external beam radiation therapy in locally advanced rectal cancer. J Egypt Natl Canc Inst 2008;20:10–16. PMID:
19847277.
28. Falk AT, Claren A, Benezery K, François E, Gautier M, Gerard JP, et al. Interstitial high-dose rate brachytherapy as boost for anal canal cancer. Radiat Oncol 2014;9:240PMID:
25377886.
29. Stojanovic S, Radosevic-Jelic I, Dabic-Stankovic K, Popov I, Josifovski J. External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. Acta Chir Iugosl 2007;54:33–38. PMID:
17988027.
30. Sun Myint A, Lee CD, Snee AJ, Perkins K, Jelley FE, Wong H. High dose rate brachytherapy as a boost after preoperative chemoradiotherapy for more advanced rectal tumours: the Clatterbridge experience. Clin Oncol (R Coll Radiol) 2007;19:711–719. PMID:
17884396.
31. Lestrade L, De Bari B, Montbarbon X, Pommier P, Carrie C. Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis. Med Oncol 2013;30:402PMID:
23322520.
32. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 2012;84:949–954. PMID:
22592048.
33. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99–107. PMID:
18407433.
34. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835–844. PMID:
20692872.
35. Lee KH, Song MS, Park JB, Kim JS, Kang DY, Kim JY. A phase II study of additional four-week chemotherapy with capecitabine during the resting periods after six-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Ann Coloproctol 2013;29:192–197. PMID:
24278857.
36. Meyer J, Balch G, Willett C, Czito B. Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. Curr Oncol Rep 2011;13:177–185. PMID:
21465120.